Check out the companies that make headlines before the opening bell on Wall Street. US Steel – U.S. Steel stocks rose 5% by 5% after approved Japan’s merger with Japanese Steel on Friday. The companies have also signed a national security agreement that includes a golden share of the US government. Although US steel had not specified the authority the government should exercise on its distribution, Trump said Thursday that Golden Share would give the US president “full control.” Roku – The streaming platform jumped 8.5% after announcing an exclusive partnership with Amazon. The agreement allows advertisers to reach approximately 80 million US households through the Amazon platform. Advanced Micro Devices – Chipmakers added more than 2% after price targets increased from Piper Sandler. After AMD’s close quarterly pre-quarterly call on Friday, Piper said it anticipated AMD’s artificial intelligence business would surge after the third quarter when China-related charges were passed, and it looked at the rise in convictions among investors about a major hyperschool client. ECHOSTAR – Satellite companies jumped over 40% after Bloomberg News reported late Friday that President Donald Trump had pushed head of the Federal Communications Commission to resolve the spectrum dispute. The company has threatened to file for bankruptcy protection, claiming that the FCC threat has blocked its ability to decide to build out 5G networks. celsius – After TD Cowen upgraded the stock and Buy, Energy Drink Company’s shares rose about 4%. The investment bank said it is confident in the smooth integration of its acquisition of the celsius brand, the company Alani Nu, and its wide distribution next year. Victoria’s Secret – Stocks added 3% following reports that activist investor Barrington Capital Group has built a stock in the retailer. Barington said he was trying to push Victoria’s secrets to overhaul the board and refocus the business, the Wall Street Journal said it was citing an unknown source. Sage Therapeutics – Sage surged 35% after Sage Supernus Pharmaceuticals agreed to acquire it in a deal worth $12 per share, or a deal worth $795 million. According to the statement, the deal will diversify Supernus’ revenue base and add a treatment for FDA-approved postnatal depression drugs Zurzuvae. Sage shareholders will receive one share of cash and one share of $8.50 for certain specific milestones worth $3.50 per share. Sarepta Therapeutics – The biopharmaceutical company has surpassed more than 37% after Sarepta reported the death of a second patient who received Elevedi gene therapy for Duchenne muscular dystrophy. Salepta has stopped Yerevidi’s cargo and is taking steps to improve the safety of non-American patients. – Reported by CNBC’s Jesse Pound and Michelle Fox.
US Steel, Roku, etc.
